Primary biliary cholangitis (PBC), previously known as primary biliary "cirrhosis", is a rare autoimmune liver disease characterized by ...
Intercept Pharmaceuticals, Inc.has announced that the FDA has granted accelerated approval to Ocaliva (obeticholic acid) for the treatment of primary...
Intercept Pharmaceuticals has announced that the New England Journal of Medicine published the key results of the Phase III POISE...
Intercept Pharmaceuticals has announced results from three new exploratory analyses of the Phase III POISE trial of Ocaliva (obeticholic acid)...
Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in...
Intercept Pharmaceuticals, Inc.announced that the European Commission has granted conditional approval for Ocaliva (obeticholic acid) for the treatment of primary...
Intercept Pharmaceuticals has announced the results of two new analyses of the POISE trial, the Phase III trial of Ocaliva...
Background: We previously showed that increased asymmetric dimethylarginine (ADMA) biliary excretion occurs during hepatic ischemia/reperfusion (I/R), prompting us to study the effects of the farnesoid X receptor (FXR)...
Ocaliva is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
The FDA’s Gastrointestinal Drugs Advisory Committee voted 17 to 0 to recommend accelerated approval of Ocaliva (obeticholic acid), from Intercept...